FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Nifedipine (Adalat, BAYA1040) and Valsartan
Nifedipine (Adalat, BAYA1040)
Valsartan
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Central blood pressure, Nifedipine, Valsartan
Eligibility Criteria
Inclusion Criteria:
- Untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure (BP) >/= 100 and/or mean systolic BP >/= 160mmHg without anti-hypertensive treatment or Treated grade 2 hypertension defined by mean diastolic BP >/= 100 and/or mean systolic BP >/=160mmHg with current diuretics and/or beta-blockers use for >/= 4 weeks
Exclusion Criteria:
- Secondary form of hypertension
- Mean systolic BP >/= 200mmHg and or mean diastolic BP >/= 120mmHg
- Treated with other antihypertensive medication except diuretics or beta-blockers
- Type 1 diabetes mellitus
- Known cardiovascular disease including history of angina pectoris, heart failure, history of myocardial infarction or revascularization procedure, or cerebrovascular disease (including stroke and transient ischaemic attack) within the previous 12 months
- Renal insufficiency defined as a serum creatinine: >/= 1.7 mg/dl
- Pregnancy or not using contraceptive in childbearing aged women
- Breast feeding women
- Any disease or condition that in the opinion of the investigator may interfere with completion of the study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
Arm 1
Arm 2
Arm 3
Arm Description
Outcomes
Primary Outcome Measures
Central systolic blood pressure
Secondary Outcome Measures
Change in central diastolic blood pressure and pulse pressure
Change in central systolic blood pressure
Change in brachial systolic blood pressure and diastolic blood pressure
Change in brachial pulse pressure
Change in augmentation index and augmentation pressure
Response rate(≥10 mmHg decrease of brachial SBP and ≥5mmHg decrease of brachial DBP)
Control rate (≤140/90 mmHg, 130/80 mmHg for diabetes, of brachial BP
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01071122
Brief Title
FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
Official Title
A Prospective, Open-label, Active-controlled, Randomized Study Comparing Nifedipine GITS Versus Valsartan Versus a Combination of Both on Central Blood Pressure in Inadequately Controlled Essential Hypertension.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
February 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To determine whether the combination of nifedipine GITS and valsartan is more effective in reducing central blood pressure than nifedipine GITS or valsartan alone, and to determine whether nifedipine GITS is comparable to valsartan
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Central blood pressure, Nifedipine, Valsartan
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
365 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm 1
Arm Type
Experimental
Arm Title
Arm 2
Arm Type
Active Comparator
Arm Title
Arm 3
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Nifedipine (Adalat, BAYA1040) and Valsartan
Intervention Description
Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
Intervention Type
Drug
Intervention Name(s)
Nifedipine (Adalat, BAYA1040)
Intervention Description
Nifedipine 60mg, Once daily
Intervention Type
Drug
Intervention Name(s)
Valsartan
Intervention Description
Valsartan 160mg, Once daily
Primary Outcome Measure Information:
Title
Central systolic blood pressure
Time Frame
Week 8
Secondary Outcome Measure Information:
Title
Change in central diastolic blood pressure and pulse pressure
Time Frame
Week 4,8
Title
Change in central systolic blood pressure
Time Frame
Week 4
Title
Change in brachial systolic blood pressure and diastolic blood pressure
Time Frame
Week 4,8
Title
Change in brachial pulse pressure
Time Frame
Week4,8
Title
Change in augmentation index and augmentation pressure
Time Frame
Week 4,8
Title
Response rate(≥10 mmHg decrease of brachial SBP and ≥5mmHg decrease of brachial DBP)
Time Frame
Week 4,8
Title
Control rate (≤140/90 mmHg, 130/80 mmHg for diabetes, of brachial BP
Time Frame
Week 4,8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure (BP) >/= 100 and/or mean systolic BP >/= 160mmHg without anti-hypertensive treatment or Treated grade 2 hypertension defined by mean diastolic BP >/= 100 and/or mean systolic BP >/=160mmHg with current diuretics and/or beta-blockers use for >/= 4 weeks
Exclusion Criteria:
Secondary form of hypertension
Mean systolic BP >/= 200mmHg and or mean diastolic BP >/= 120mmHg
Treated with other antihypertensive medication except diuretics or beta-blockers
Type 1 diabetes mellitus
Known cardiovascular disease including history of angina pectoris, heart failure, history of myocardial infarction or revascularization procedure, or cerebrovascular disease (including stroke and transient ischaemic attack) within the previous 12 months
Renal insufficiency defined as a serum creatinine: >/= 1.7 mg/dl
Pregnancy or not using contraceptive in childbearing aged women
Breast feeding women
Any disease or condition that in the opinion of the investigator may interfere with completion of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Official's Role
Study Director
Facility Information:
City
Goyang-si
State/Province
Gyeonggido
ZIP/Postal Code
411-706
Country
Korea, Republic of
City
Goyang
State/Province
Gyeonggido
ZIP/Postal Code
410-773
Country
Korea, Republic of
City
Chungchungbuk-do
State/Province
Korea
ZIP/Postal Code
361-711
Country
Korea, Republic of
City
Seoul
State/Province
Korea
ZIP/Postal Code
135-720
Country
Korea, Republic of
City
Seoul
State/Province
Seoul Teugbyeolsi
ZIP/Postal Code
152-703
Country
Korea, Republic of
City
Busan
Country
Korea, Republic of
City
Gwangju
ZIP/Postal Code
501-757
Country
Korea, Republic of
City
Joong-gu
ZIP/Postal Code
100-380
Country
Korea, Republic of
City
Kungki-do
ZIP/Postal Code
463-707
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
135-710
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
136-705
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
137-701
Country
Korea, Republic of
City
Suwan
ZIP/Postal Code
443-721
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
26996246
Citation
Park JB, Shin JH, Kim DS, Youn HJ, Park SW, Shim WJ, Park CG, Kim DW, Lee HY, Choi DJ, Rim SJ, Lee SY, Kim JH; FOCUS Investigators. Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: the FOCUS Study. Clin Ther. 2016 Apr;38(4):832-42. doi: 10.1016/j.clinthera.2016.02.025. Epub 2016 Mar 17.
Results Reference
derived
Learn more about this trial
FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
We'll reach out to this number within 24 hrs